← Back to Screener
Zura Bio Limited Class A Ordinary Shares (ZURA)
Price$3.40
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-19.38%
Price vs S&P 500 (4W)-29.01%
VGM Score42.41
Market Capitalization$366.69M
All Metrics
Book Value / Share (Quarterly)$2.29
P/TBV (Annual)1.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.77
Price vs S&P 500 (YTD)-43.27%
EPS (TTM)$-0.75
10-Day Avg Trading Volume1.11M
EPS Excl Extra (TTM)$-0.75
EPS (Annual)$-0.72
ROI (Annual)-35.69%
Cash / Share (Quarterly)$2.38
ROA (Last FY)-29.19%
EBITD / Share (TTM)$-0.82
Cash Flow / Share (Annual)$-0.51
P/B Ratio1.69x
P/B Ratio (Quarterly)2.60x
Net Income / Employee (Annual)$-1,695,500
ROA (TTM)-46.31%
EPS Incl Extra (Annual)$-0.72
Current Ratio (Annual)9.16x
Quick Ratio (Quarterly)19.21x
3-Month Avg Trading Volume0.65M
52-Week Price Return195.65%
EV / Free Cash Flow (Annual)52.05x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.47
52-Week High$7.44
EPS Excl Extra (Annual)$-0.72
26-Week Price Return-11.46%
Quick Ratio (Annual)9.04x
13-Week Price Return-49.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.33x
Enterprise Value$141.10M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.70
3-Month Return Std Dev66.55%
Net Income / Employee (TTM)$-1,865,000
ROE (Last FY)-35.69%
EPS Basic Excl Extra (Annual)$-0.72
EV / Free Cash Flow (TTM)156.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.75
ROI (TTM)-54.00%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.75
Price vs S&P 500 (52W)171.29%
Year-to-Date Return-35.11%
5-Day Price Return-19.81%
EPS Normalized (Annual)$-0.72
Month-to-Date Return-20.93%
Cash Flow / Share (TTM)$0.03
EBITD / Share (Annual)$-0.80
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.75
P/TBV (Quarterly)2.92x
P/B Ratio (Annual)1.11x
Book Value / Share (Annual)$2.25
Price vs S&P 500 (13W)-57.96%
Beta0.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-54.00%
52-Week Low$1.00
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.22est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.36
4.36
4.36
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZURAZura Bio Limited Class A Ordinary Shares | — | — | C | $3.40 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Zura Bio Ltd is a clinical-stage immunology company developing novel dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company has three lead programs that have completed Phase I/Ib studies and are advancing to Phase II trials. Its pipeline includes tibulizumab and torudokimab, which are being evaluated for efficacy, safety, and dosing convenience across multiple therapeutic indications.